HEPC病毒无干扰疗法看起来很有希望
![For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease inhibitor ABT-450, combined with low-dose ritonavir plus the nonnucleoside NS5B polymerase inhibitor ABT-333 and ribavirin, seems effective for genotype 1, according to two studies published in the Jan. 2 issue of the <i>New England Journal of Medicine</i>. HEPC病毒无干扰疗法看起来很有希望](https://scx1.b-cdn.net/csz/news/800a/2013/interferonfr.jpg)
(HealthDay) -对于未经治疗的丙型肝炎病毒(HCV)患者,使用口服丙型肝炎病毒聚合酶核苷酸抑制剂sofosbuvir联合利巴韦林治疗似乎对基因型1、2和3有效;而HCV NS3蛋白酶抑制剂ABT-450,联合小剂量利托那韦(ABT-450/r)、非核苷NS5B聚合酶抑制剂ABT-333和利巴韦林,似乎对基因1型有效,根据发表在1月2日的两项研究新英格兰医学杂志。
新西兰奥克兰城市医院的Edward J. Gane医学博士及其同事评估了sofosbuvir在干扰素保留和无干扰素治疗未治疗的HCV基因型2和3患者中的作用。在24周的治疗后,研究人员发现,所有接受sofosbuvir +利巴韦林(不使用干扰素或使用干扰素)的患者都有持续的病毒学应答。此外,84%的既往未治疗的HCV基因型1患者对sofosbuvir和利巴韦林有持续的病毒学应答。
In a second study, Fred Poordad, M.D., from the University of Texas Health Science Center in San Antonio, and colleagues assessed the role of ABT-450/r, ABT-333, and ribavirin for treatment of HCV 1 infection without cirrhosis in a 12-week phase 2a study. The researchers found that most untreated patients had an extended rapid virologic response, and 93 to 95 percent had a sustained virologic response 12 weeks after the end of treatment. Forty-seven percent of those who had had a null or partial response to previous therapy with peginterferon and ribavirin had sustained病毒学反应治疗后12周。
“这项初步研究表明,12周的治疗与a蛋白酶抑制剂一种非核苷聚合酶抑制剂,和利巴韦林可能对治疗基因1型HCV感染有效,”Poordad和他的同事总结说。
Gane研究得到了Pharmasset和Gilead Sciences的支持;Poordad学习由Abbott资助。
版权所有©2013.健康天。版权所有。
用户评论